Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism

Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways
Xinqi Wu, Jingjing Li, Meijun Zhu, Jonathan A. Fletcher, and F. Stephen Hodi

Targeted Expression of BikDD Eliminates Breast Cancer with Virtually No Toxicity in Noninvasive Imaging Models
Nousheen Zaidi, Ines Royaux, Johannes V. Swinnen, and Karine Smans

Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts
Muralidharan Anbalagan, Alaa Ali, Ryan K. Jones, Carolyn G. Marsden, Mei Sheng, Latonya Carrier, Yahao Bu, David Hangauer, and Brian G. Rowan
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models

Caroline C. Clark, Jeffrey N. Weitzel, and Timothy R. O’Connor

TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

Daniel P. Fitzgerald, David L. Emerson, Yongzhen Qian, Talha Anwar, Hong-Bin Fang, Ling Cai, Zhe-Sheng Chen, Suresh V. Ambudkar, and Maria R. Baer

Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target

Yongli Guo, Fadzai Chinyengetere, Andrey V. Dolinko, Alexandra Lopez-Aguilar, Yun Lu, Fabrizio Galimberti, Tian Ma, Qing Feng, David Sekula, Sarah J. Freemantle, Angela S. Andrew, Vincent Memoli, and Ethan Dmitrovsky

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib


YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels

Bhavna Kumar, Arti Yadav, James C. Lang, Michael J. Cipolla, Alessandra C. Schmitt, Nicholas Arradaza, Theodoros N. Teknos, and Pawan Kumar

The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

Masamichi Mizuma, Zeshaan A. Rasheed, Shinsuke Fujiwara, Alessandra C. Schmitt, Nathan R. Campbell, Amanda L. Campbell, Elizabeth De Oliveira, Qing Zhang, Oscar Puig, William Matsui, Manuel Hidalgo, Anirban Maitra, and Dennis L. Slamon

Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells

Yoko Matsuda, Masahito Hagi, Tomoko Saya, and Toshiyuki Ishiwata

Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion


The Novel BCR-ABL and FLT3 Inhibitor Ponatinib Is a Potent Inhibitor of the MDR-Associated ATP-Binding Cassette Transporter ABCG2

Rupashree Sen, Karthika Natarajan, Jasjeet Bhullar, Suneet Shukla, Mark S. Qian, Debra Liao, Ray Liu, Denise Driscoll, Michelle Tighe, Benjamin S. Amidon, Youlan Rao, Matt O. Duffey, Mark G. Manfredi, Tricia J. Vos, Natalie D’Amore, and Marc L. Hyer

MLN0905, a Small-Molecule PLK1 Inhibitor, Induces Antitumor Responses in Human Models of Diffuse Large B-cell Lymphoma

Judy Quiju Shi, Kerri Lasky, Vanhali Shinde, Bradley Stringer, Mark G. Qian, Debra Liao, Ray Liu, Denise Driscoll, Michelle Tighe, Benjamin S. Amidon, Youlan Rao, Matt O. Duffey, Mark G. Manfredi, Tricia J. Vos, Natalie D’Amore, and Marc L. Hyer

Genetic Variation That Predicts Platinum Sensitivity Reveals the Role of miR-193b* in Chemotherapeutic Susceptibility

Dana Ziliak, Eric R. Gamazon, Bonnie LaCroix, Hae Kyung Im, Yuja Wen, and Rong Stephanie Huang

Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors


Correction: Proanthocyanidins Inhibit In Vitro and In Vivo Growth of Human Non–Small Cell Lung Cancer Cells by Inhibiting the Prostaglandin E2 and Prostaglandin E2 Receptors

ABOUT THE COVER

Immunohistochemical staining of colorectal cancer tissues using anti-FGFR2IIIc antibody. The tumor cell cytoplasm and cell membrane of adenocarcinoma showed strong immunoreactivity for FGFR2IIIc, which is a splicing isoform of FGFR2. FGFR2IIIc immunoreactivity was expressed in 27% of colorectal cancer cases, and this expression correlated with distant metastasis and poor prognosis. FGFR2IIIc-transfected colorectal cancer cells formed larger tumors in subcutaneous tissues and the cecum of immunodeficient mice. Fully human anti-FGFR2IIIc monoclonal antibody inhibited the growth and migration of colorectal cancer cells. For details, see the article by Matsuda and colleagues on page 2010.